(Q33809610)

29 July 2017

1 reference

title

Treatment of chronic hepatitis C: comparative virologic response rates among the different interferons (English)

1 reference

29 July 2017

0 references

1 reference

1 reference

K L Lindsay

1

1 reference

29 July 2017

publication date

1 January 1999

1 reference

29 July 2017

published in

Journal of Hepatology

1 reference

29 July 2017

volume

31 Suppl 1

1 reference

29 July 2017

page(s)

232-236

1 reference

Therapy of hepatitis C: overview

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980408-5

7 January 2021

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980408-5

7 January 2021

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980408-5

7 January 2021

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980408-5

7 January 2021

Re-treatment of chronic hepatitis C with consensus interferon .

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980408-5

7 January 2021

Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980408-5

7 January 2021

Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980408-5

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980408-5

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980408-5

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980408-5

7 January 2021

10.1016/S0168-8278(99)80408-5

Identifiers

DOI

1 reference

29 July 2017

1 reference